Kornimate/medical-research-clean huggingface dataset:
bis monitoring in relation to muscle relaxant administration

Conditions: Cardiovascular Surgery; Bispectral Index; Anesthesia

Summary: the purpose of this study is to determine the overall optimal timing of when the bispectral index (bis) monitor should be started: before or after the muscle relaxant is given.


Eligibility criteria:
inclusion criteria: * undergoing elective cardiac surgery * muscle relaxation administration by rocuronium exclusion criteria: * patient refusal * pediatric patients * emergency procedure * patients with known or suspected carotid or cerebrovascular disease * patients with prior stroke * skin condition or anatomy preventing proper sensor placement * patients who receive ketamine during the study timeframe

Keywords: bis paralysis
pharmacokinetic study to evaluate the extent of systemic absorption of pep005

Conditions: Actinic Keratoses

Summary: the purpose of this study is to determine the extent of systemic absorption of pep005 when applied topically for the treatment of actinic keratoses.

actinic keratoses (ak) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. non-invasive alternative therapy for treatment of ak lesions is thus being researched.

Eligibility criteria:
inclusion criteria: 1. male patients at least 18 years of age. 2. a contiguous 100 cm2 treatment area containing at least 5 ak lesions, on the either the right or left extensor (dorsal aspect) forearm. 3. written informed consent has been obtained. 4. agreement from the patient to allow photographs of the selected ak treatment area to be taken and used as part of the study package.

Keywords: pharmacokinetic study actinic keratosis topical dermatology
a clinical study on fasudil hydrochloride for treatment of gene-specific ovarian cancer

Conditions: Ovarian Cancer

Summary: this is a prospective study investigating whether the research on fasudil hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (nsclc) and other tumors. the study plans to enroll 20 patients with a/a genotype ovarian cancer for treatment evaluation.

ovarian cancer is a common gynecological malignancy with the highest mortality rate among gynecological cancers. the poor prognosis and low survival rate in advanced-stage patients primarily contribute to its high mortality. current clinical management of malignant ovarian tumors relies on postoperative chemotherapy and radiotherapy, which impose significant harm to the human body and offer limited improvement in patient prognosis. additionally, the diagnostic and therapeutic cycle for malignant ovarian cancer is prolonged and unpredictable, predominantly focusing on post-surgical interventions. in our preliminary studies, we identified that the a allele of snp-rs1192691, associated with ovarian cancer prognosis, promotes ovarian cancer cell proliferation and invasion by activating the rho signaling pathway. the rho signaling pathway inhibitor fasudil has been shown to effectively suppress the proliferation and invasion of a/a genotype tumor cells in murine models. this study aims to investigate the therapeutic efficacy of fasudil in a/a genotype ovarian cancer patients through clinical trials, with the goal of improving their prognosis.

Eligibility criteria:
inclusion criteria: 1. patients voluntarily participate in the study, sign informed consent forms, and have good compliance. 2. after platinum based chemotherapy at zhejiang provincial people's hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (sd) or disease progression (pd) twice were treated with fasudil in combination with the original chemotherapy regimen, and were confirmed to have the a/a genotype through genetic testing. exclusion criteria: * 1.accompanied by hypotension 2. bleeding like cerebral hemorrhage 3. patients with abnormal liver function

Keywords: ovarian cancer fasudil hydrochloride
sleep disturbances in dermatology patients

Conditions: Sleep Disorder

Summary: this study is to investigate sleep disorders in patients with dermatologic diseases by taking into consideration dermatologic (itch, pain) and non- dermatologic (medication, depression) factors.


Eligibility criteria:
inclusion criteria: * outpatients of the dermatologic university clinic exclusion criteria: * insufficient knowledge of german language * illiteracy

Keywords: dermatologic disease
study of optimal treatment plan in hypertensives with anti-at1-receptor autoantibody

Conditions: Hypertension

Summary: the autoantibodies against at1 receptor (atr-aa), behaving like an agonist were detected in patients with hypertension. atr-aa which can blocked by arb may play a role in the pathogenesis of hypertension. the present study is to explore whether at1 receptor blocker has superior anti-hypertensive effect in patients with positive atr-aa hypertension. patients with 2 grade hypertension were recruited and atr-aa was assayed by elisa. a study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ace inhibitor imidapril.


Eligibility criteria:
inclusion criteria: * hypertension (2 grade) exclusion criteria: * secondary hypertension * known sensitivity or intolerance to an angiotensin ii receptor antagonist or ace inhibitor * pregnancy
surveillance among healthcare workers for sars-coronavirus-2 infection

Conditions: COVID-19; SARS-CoV2 Infection

Summary: this study aims to investigate the epidemiology of sars-cov-2 infection among: i) hcw who triage patients with suspected sars-cov-2 infection and provide care to covid-19 patients; and ii) laboratory personnel who test clinical samples for sars-cov-2 infection. after the second wave of the pandemic enrolment will be widen to any person working at the study hospitals.


Eligibility criteria:
inclusion criteria: * hcws of any staff category at the study hospitals. exclusion criteria: * none
a study of improving education of community chain of survival

Conditions: Cardiac Arrest Circulatory

Summary: "high-quality cardiopulmonary resuscitation (cpr)" and "early defibrillation" are the most important parts of "the chain of survival", and they are highly associated with the survival rate and life quality of patients with cardiac arrest. it needs the witness to perform bystander cpr and use the automated external defibrillator (aed) if cpr and defibrillation are expected to be performed earlier. nevertheless, few patients with cardiac arrest received bystander cpr in taiwan. it might be caused by some reasons. first, traditional training programs were inefficient and ineffective in the retention of skills and thus students were not confident in their cpr skills after receiving training programs. second, the current training module focused on personal skill training only and lacked teamwork skills training. it led to poor performance of the students in actual resuscitation scene, where on-scene resuscitators were usually more than one. third, the current training contents did not improve the attitudes and willingness of performing bystander cpr and it caused people who had received training program did not resuscitate the patients finally. to improve the above-mentioned problem, a three-year research project will be implemented. the aims of the project are the following: 1. to explore the effect of different teaching contents and hand-on practice feedback methods on the students' performance of chest compressing, ventilating and using aed in the cpr and aed training courses. 2. to analyze the current situation of teamwork when cpr and aed were performed, to build up the collaborating module accordingly and evaluate the effect of the new module on the students' performance of chest compressing, ventilating and using aed after the module is introduced into the training course. 3. to understand the factors affecting the motivations and willingness of people to learn and practice cpr and aed by utilizing questionnaires, and then to evaluate the effect of the creative program, which was modified according to the results of the questionnaires, on the motivations and willingness of people to learn and practice cpr and aed. the investigators expect to design a more efficient resuscitation skill training course by implementing the research project and further to improve the motivations and willingness of people to learn and practice cpr and aed in the future.


Eligibility criteria:
inclusion criteria: * healthy laypersons without cpr training within two years exclusion criteria: * non
de-escalation of opioids post-surgical discharge

Conditions: Opioid Dependence

Summary: the descale study aims to: 1. look at the prescribing trends of opioids and the scale of long-term use following surgery within east kent (united kingdom) 2. carry out a feasibility study to: * see if clinical pharmacists can support patients following surgery to manage their post-surgical pain safely and prevent long-term opioid use * calculate how much it costs the national health service (nhs) * see how the patients experienced the intervention for aim 1, historic records of patients who have had surgery and were discharged on opioids will be reviewed. data collected will include type and strength of pain-relieving medication prescribed; type of surgery; number of additional opioid prescriptions following discharge; use of medical services (e.g., general practice appointments, physiotherapy); and patient demographics. for aim 2, clinical pharmacists will carry out early high-risk medication safety reviews to ensure that patients have their pain managed safely. investigators will collect key data from patients receiving the clinical pharmacist intervention to see how it affected opioid use, costs and healthcare use. patients who took part in the study will be invited to participate in an interview and will be asked what they know about opioids and the health risks, and their experiences of the intervention.


Eligibility criteria:
inclusion criteria: * aged 18 years old or above. * undergone surgery and discharged with opioid medication\* less than 120mg mme/day from a participating hospital and taking it for the treatment of acute non-malignant post-surgical pain. * investigators have used the british national formulary (bnf) definition of opioids and will recruit participants who have been prescribed one or more of the following drugs: codeine, dihydrocodeine, buprenorphine transdermal patches, fentanyl transdermal patches, morphine, oxycodone, tramadol, diamorphine, dipipanone, tapentadol, pentazocine. exclusion criteria: * aged under 18 years of age. * unable to provide written informed consent. * more than 90 days opioid use pre-surgery. * on \> 120 mg mme/day. * additional surgical procedures planned during the 3-month intervention. * a history of methadone treatment. * regularly inject opioids. * using opioids for malignant pain. * undergone a caesarean section. * is pregnant\*. * classified as vulnerable (e.g., severe dementia, severe co-existing or terminal medical condition). * risk of miscarriage or stillbirth from opioid withdrawal

Keywords: prescribing surgery pain de-escalation
onabotulinumtoxina injections in chronic migraine, targeted to sites of pericranial myofascial pain

Conditions: Chronic Migraine

Summary: this study was an observational, open-label, cohort-study conducted in accordance with the principles of the helsinki declaration. we prospectively and systematically recorded data from the patients and analyzed them retrospectively. during a first phase, called adaptation period, the injector (dr) used a follow-the-pain approach in order to determine the optimal injection scheme for each individual. the possible injection sites were the corrugator, temporalis, and trapezius muscles. patients were systematically asked about the usual topography and time course of migraine attacks, and the existence of pain or stiffness of the cervical muscles. if the pain was predominantly located in the frontotemporal area, the corrugator and temporalis muscles were injected bilaterally. when the patients had predominant pain in the back of the head, or when their headache pain frequently started and/or ended in the trapezius muscles, both trapezius muscles were injected. these muscle groups were injected together if pain was both frontotemporal and cervico-occipital. when this first set of injections was efficacious, patients were re-injected in the same manner at the time when the frequency of headache days definitely increased. in the absence of efficacy, the paradigm was modified using the same follow-the-pain approach. once the best procedure was determined for each patient, it was reproduced at each subsequent injection session. this adaptation phase could necessitate up to three sessions. the observation period started 8 weeks before the first efficacious injection and ended 2 months after the second consecutive efficacious injection, or in case of inefficacy. throughout the adaptation and the observation phases, patients kept a headache diary where they were asked to note the days with headache and the use of rescue medication.


Eligibility criteria:
inclusion criteria: * patients refractory to conventional treatments exclusion criteria: * contra-indication to botulinum toxin treatment inability to sign informed consent

Keywords: onabotulinumtoxina, chronic migraine, myofascial pain
spinal cord stimulation and physiotherapy for treatment of neuropathic pain

Conditions: Neuropathic Pain

Summary: the study evaluates the combined effect of optimized pharmacological treatment, spinal cord stimulation and physiotherapy on pain relief, health-related quality of life and physical function in patients with neuropathic pain. all patients will receive optimized pharmacological treatment before start of spinal cord stimulation treatment. half of the participants will be randomized to physiotherapy before start of spinal cord stimulation treatment while the other half will start physiotherapy after spinal cord stimulation treatment.

previous studies have indicated that almost half of the patients with moderate-severe pain receive inadequate pain relief. neuropathic pain is a common pain condition, affecting 1.5-8% of the population. conventional pharmacological treatment reduces pain but is often insufficient. spinal cord stimulation (scs) is associated with improved pain relief and health-related quality of life compared to conventional medical management. despite scs treatment, only half of the patients report \>50% pain relief. other studies have indicated that active, specific physiotherapy led by professionals reduces pain in chronic pain conditions. the aim of the study is to access the combined effect of optimized pharmacological treatment, scs and physiotherapy on pain relief, health-related quality of life and physical function in patients with neuropathic pain. furthermore, the study evaluates when it is most effective to start the physiotherapy.

Eligibility criteria:
inclusion criteria: * neuropathic pain \> 6 months * pain intensity ≥ 5 according to nrs (for neuropathic pain component to be treated with scs) * known cause of the pain * neuroanatomical correlation to the pain * ≥50% of the painful area is to be treated with scs * the patient has a physical and psychological health status that allows the patient to participate in physiotherapy and undergo scs implantation. exclusion criteria: * not able to undergo scs implantation * inadequate knowledge of the swedish language * alcohol or substance abuse * severe untreated psychiatric disorders including psychiatric disease and/or psychological conditions which are the primary determinant to the patient's pain condition * incapacitating pain conditions of other causes than neuropathic pain * pregnancy * insufficient compliance * malignant disease with short expected survival

Keywords: pain quality of life electric stimulation therapy physiotherapy
ablate post approval study - synergy ablation lesions for non-paroxysmal atrial fibrillation

Conditions: Persistent Atrial Fibrillation; Longstanding Persistent Atrial Fibrillation

Summary: the primary objective of this post-approval study is to evaluate the clinical outcomes in a cohort of patients with non-paroxysmal forms of atrial fibrillation (persistent or long-standing persistent) treated during commercial use of the atricure synergy ablation system by physicians performed the maze iv procedure.

this prospective, open label, multi-center, observational, single arm registry is designed to monitor the atricure synergy ablation system continued safety and efficacy during the peri-procedural and long-term phase during commercial use in patients being treated for non-paroxysmal forms of atrial fibrillation who are undergoing a concomitant open, on-pump cardiac surgical procedure.

Eligibility criteria:
inclusion criteria: * age \> or equal to 18 years of age * history of non-paroxysmal form of atrial fibrillation (af) as defined by the heart rhythm society/european heart rhythm association/european cardiac arrhythmia society consensus statement: * persistent af shall be defined as continuous af that is sustained beyond seven days. episodes of af in which a decision is made to electrically or pharmacologically cardiovert the patient after greater than or equal to 48 hours of af but prior to 7 days, should also be classified as persistent af episodes. * longstanding persistent af shall be defined as continuous af of greater than 12 months duration. the performance of a successful cardioversion (sinus rhythm \>30 seconds) within 12 months of an ablation procedure with documented early recurrence of af with 30 days should not alter the classification of af as longstanding persistent. * subject is scheduled to undergo elective open cardiac surgical procedure(s) to be performed on cardiopulmonary bypass for one or more of the following: coronary artery bypass grafting, mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement. in conjunction with these procedure patent foramen ovale (pfo) or atrial septal defect (asd) repair are allowed. * the patient (or their legally authorized representative) agrees to participate in this study by singing the institutional review board (irb) approved informed consent form. * willing and able to return for scheduled follow up visits. exclusion criteria: * stand along af without indication(s) for concomitant cardiac surgery. * need for emergent cardiac surgery (i.e., cardiogenic shock). * preoperative need for an intra-aortic balloon pump or intravenous inotropes. * pregnancy or desire to get pregnant for the duration of the study concomitant surgical procedure through the thirty six (36) month follow up period). * enrolled in another clinical trial that could confound the results of this study.

Keywords: atrial fibrillation
platelet rich plasma injections for vulvar lichen sclerosus

Conditions: Lichen Sclerosus

Summary: 15 patients with biopsy proven active vulvar lichen sclerosus will be recruited by a clinic specializing in vulvar disorders. this study consists of a 2 week screening period and a 12-week treatment period. participants will receive two separate treatments of autologous platelet rich plasma separated by 6 weeks. a repeat biopsy will be performed 6 weeks after the second autologous platelet rich plasma injection

15 patients with biopsy proven active vulvar lichen sclerosus will be recruited by a clinic specializing in vulvar disorders. this study consists of a 2 week screening period. a 4mm vulvar punch biopsy will be obtained at the initiation of the screening period to confirm that the participant have active lichen sclerosus. 12 weeks after the biopsy, the participants will receive an injection of 5cc of autologous platelet rich plasma into the affected vulvar skin. six weeks later, participants will receive an additional injection of 5cc of autologous platelet rich plasma. a repeat biopsy will be performed 6 weeks after the second autologous platelet rich plasma injection. the inflammation on both biopsy specimens will be determined by a dermatopathologist.

Eligibility criteria:
inclusion criteria: * active lichen sclerosus * no current treatment * symptomatic 4/10 on visual analogue scale exclusion criteria: * history of vulvar carcinoma or vin
predictors of success in an intervention program for the treatment of childhood obesity

Conditions: Childhood Obesity

Summary: the child health and sports center, at the meir medical center, runs for over 10 years an intervention program to treat obese children. the program includes physical activity, nutritional intervention and behavioral treatment. a similar program exists in the nearby city of hadera. the aim of the programs is to promote weight loss, encourage physical activity and modify behavior in order to get long term results. the aim of the present study is to try and identify the demographic and behavioral characteristics of children who succeed in the program.


Eligibility criteria:
inclusion criteria: * obese / overweight children exclusion criteria: * children that has an organic illness that cause obesity

Keywords: childhood obesity adolescence predictors success intervention program
skin toxicity treatment in metastatic colorectal cancer (mcrc) patients receiving panitumumab + irinotecan-based therapy

Conditions: Metastatic Colorectal Cancer; Skin Rash; Skin Toxicities; Colon Cancer; Colorectal Cancer

Summary: a comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mcrc) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.


Eligibility criteria:
inclusion criteria: * patients with unresectable metastatic adenocarcinoma of the colon or rectum that cannot, in the opinion of the investigator, be cured by surgical resection at the time of randomization; * patients who have failed first line treatment containing fluoropyrimidine and oxaliplatin based chemotherapy with or without bevacizumab for mcrc. exclusion criteria: • prior irinotecan use for the treatment of mcrc.

Keywords: stepp step steep mcrc skin toxicities skin rash metastatic colorectal cancer anti-egfr skin rash colon cancer colorectal cancer rectal cancer